The FDA can issue approval for orphan drugs which show promise in the treatment, prevention, or diagnosis of rare diseases or conditions that affect fewer than 200,000 people in the United States. Example: Zelboraf (vemurafenib) was designated as an orphan drug in 2014, and the designation expired in 2021, which means it is now an exclusive product for the originator, Roche.